Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

Scientists Map Genome For Parasite Causing Widespread Infections
Scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio have for the first time constructed a genetic map of the parasite that causes schistosomiasis, a chronic intestinal infection that can damage internal organs and, in children, impair growth and cognitive development. Schistosome parasites are flatworms that infect more than 200 million people a year worldwide. Infection results in an estimated 200,000 deaths annually in sub-Saharan Africa alone, while 20 million suffer severe disease, according to the World Health Organization.
generic viagra online
White House Officials Used Twitter, Ashton Kutcher To Promote HIV Testing Day
The White House sought the help of actor Ashton Kutcher to promote National HIV Testing Day on June 27, through his Twitter page, Politico reports. Kutcher has over 2.5 million followers on Twitter, where he recently posted a link to a White House blog post and video commemorating the day. Reid Cherlin, White House assistant press secretary, said, "As technology impacts how and where people are communicating online, we are constantly looking for new ways to engage with the public," adding, "Our efforts to promote National HIV Testing Day included participation from popular users of Twitter, as well as broad social media engagement by agencies across the government." The White House also used Twitter to help connect people to HIV testing sites (Gavin, 6/29).
News of the day
Turner Syndrome Society Of The United States Announces Ambitious Goal To Crush Ignorance Of Turner Syndrome (TS)
The Turner Syndrome Society of the United States (TSSUS) recently concluded its 22nd Annual Conference in Portland, Oregon. The conference drew more than 350 individuals, families, researchers and health care professionals to network and learn about the latest research breakthroughs benefiting women and girls with TS.
Public Health

New Drug Combination Offers Novel Treatment Strategy For Non-Hodgkin's Lymphoma

Patients diagnosed with non-Hodgkin"s lymphoma who become resistant to standard therapies may have a new treatment option. Scientists in the Lymphoma Translational Research Laboratory at Roswell Park Cancer Institute analyzed the mechanisms to overcome treatment resistance, including a new drug combination. Francisco J. Hernandez-Ilizaliturri, MD , Departments of Medicine and Immunology, Roswell Park Cancer Institute (RPCI), will present the findings at the American Society of Clinical Oncology (ASCO) 2009 annual meeting, May 29 - June 2, in Orlando, FL. "Strategies to Overcoming Rituximab-chemotherapy Resistance by Targeting the Autophagy Pathway Using Bortezomib in Combination with the Bcl-2 Inhibitor Obatoclax in non-Hodgkin"s Lymphomas (NHL)" Monday, June 1 - 5 pm EST Level 4, Valencia Room, W415A The Roswell Park investigators evaluated the biological effects of combining two drugs that target molecular pathways that play an important role in acquired resistance to standard therapies of rituximab and chemotherapy in non-Hodgkin"s lymphoma laboratory models. Obatoclax is an investigational drug designed to kill cancer cells by blocking a protein that usually prevents cell death. Bortezomib, the first approved cancer drug in a new class of medicines called proteasome inhibitors, disrupts the growth and survival of cancer cells. Scientists found that Obatoclax and Bortezomib are highly active against several lymphoma cell lines and tumor cells derived from patients with untreated or highly refractory lymphomas. When used in combination, the drugs demonstrated synergistic action. "This research contributes to the scientific understanding of the mechanisms responsible for rituximab resistance, which will ultimately result in the development of novel therapies and better outcomes for patients," said Dr. Hernandez-Ilizaliturri. "Our laboratory finding strongly suggests that Obatoclax and Bortezomib are an effective drug combination that has potential as a new treatment option for patients diagnosed with aggressive non-Hodgkin"s lymphoma and merits further investigation." The incidence of NHL has been steadily increasing over the past two decades and is now considered the second most rapidly increasing cause of cancer-related death in the United States. In 2009, approximately 65,980 new cases of NHL will be diagnosed and 19,500 patients will die from the disease. Roswell Park Cancer Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009